Sign in
TerminatedPhase 2

Proof of Concept Study Evaluating BP1.3656 in Patients With Fatigue Following Ischemic Stroke

Key facts

Who runs it
Bioprojet
Where
France and Switzerland2 sites in 2 countriesChoose a country to see its sites
Status
Terminated
Phase
Phase 2
People taking part
5 people enrolled
Started
20 Jan 2023
Ended
8 Feb 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • BP1.3656
Record updated
9 August 2024
Why it stopped
Lack of recruitment

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Males or females 18 years old or more
  • Diagnosis of ischemic stroke at least one month and not more than six months prior to screening
  • Persistent fatigue since the stroke with a score ≥ 50 across all domains of the Multidimensional Fatigue Inventory (MFI-20)
  • Modified Rankin Score (mRS) < 3
  • Capability to participate in all study tests according to the investigator
  • Patient must voluntarily express a willingness to participate in this study, sign and date an informed consent prior to any study specific procedure
  • Females of child-bearing potential must have a negative pregnancy test performed at the screening and randomization visits and use a medically accepted effective method of birth control, agree to continue this method for the duration of the study up until three weeks after last treatment intake

Who cannot take part

  • History of alcohol or drugs (i.e. cannabis, cocaine, amphetamines or opioids) (ab)use/dependence within the 12 months prior to screening or with a positive drug test at screening
  • Any identified etiology for fatigue other than stroke (except post-stroke depression) according to the investigator
  • History of psychosis
  • Current severe psychiatric disorder, e.g. schizophrenia, bipolar disorder, severe depression, or organic brain syndrome preventing the patients from completing study assessments
  • Major cognitive disorders, dementia according to the investigator
  • History of epilepsy or seizures disorder
  • Glomerular filtration rate <60 mL/min/1.73m² according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula
  • Other active clinically significant illness, infection, acid-related gastric disorder, or neoplastic pathology within the last 3 years (patients with fully cured non-melanoma skin cancer or in-situ carcinoma of the cervix are eligible) which could interfere with the study conduct or counter-indicate the study treatments or place the patient at risk during the trial or compromise his/her study participation
  • Clinically significant cardiovascular abnormalities (including clinically relevant ECG abnormalities) or, clinically significant hematological, neurological, endocrine abnormalities, severe hepatic impairment or Liver Function Tests (ASAT, ALAT) > 3 ULN, or abnormal clinical laboratory results (in most cases > 3ULN)
  • Patients at risk of suicide according to the investigator

Where is this trial?

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

Multicenter, randomized, double blind, parallel-group, placebo-controlled proof of concept study evaluating efficacy and safety of BP1.3656 in patients with fatigue following ischemic stroke.

The 2 groups in the trial

  • BP1.3656Treatment being tested

    1 tablet of 30 microgram (µg), 60µg or 90µg of BP1.3656 per day

  • PlaceboPlacebo, for comparison

    1 tablet of matching placebo per day

    Treatment: BP1.3656

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multisite Randomized Clinical Trial Evaluating Efficacy and Safety of BP1.3656 vs Placebo in Patients With Fatigue Following Ischemic Stroke
Record updated
9 August 2024